Kineta Net Income 2014-2024 | KANT
Kineta net income from 2014 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Kineta Annual Net Income
(Millions of US $) |
| 2023 |
$-14 |
| 2022 |
$-63 |
| 2021 |
$-12 |
| 2020 |
$-51 |
| 2019 |
$-31 |
| 2018 |
$-62 |
| 2017 |
$-59 |
| 2016 |
$-39 |
| 2015 |
$-23 |
| 2014 |
$-30 |
| 2013 |
$-23 |
Kineta Quarterly Net Income
(Millions of US $) |
| 2024-06-30 |
$-3 |
| 2024-03-31 |
$-10 |
| 2023-12-31 |
$-3 |
| 2023-09-30 |
$-5 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$-6 |
| 2022-12-31 |
$-47 |
| 2022-09-30 |
$-6 |
| 2022-06-30 |
$-6 |
| 2022-03-31 |
$-5 |
| 2021-12-31 |
$17 |
| 2021-09-30 |
$-10 |
| 2021-06-30 |
$-10 |
| 2021-03-31 |
$-9 |
| 2020-12-31 |
$-37 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-0 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$16 |
| 2019-09-30 |
$-13 |
| 2019-06-30 |
$-20 |
| 2019-03-31 |
$-14 |
| 2018-12-31 |
$-17 |
| 2018-09-30 |
$-18 |
| 2018-06-30 |
$-15 |
| 2018-03-31 |
$-11 |
| 2017-12-31 |
$-13 |
| 2017-09-30 |
$-14 |
| 2017-06-30 |
$-17 |
| 2017-03-31 |
$-15 |
| 2016-12-31 |
$-9 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-9 |
| 2015-12-31 |
$-6 |
| 2015-09-30 |
$-9 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$-8 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
